Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nektar Therapeutics

0.6070
+0.00140.23%
Volume:2.65M
Turnover:1.59M
Market Cap:112.96M
PE:-1.05
High:0.6235
Open:0.6100
Low:0.5700
Close:0.6056
Loading ...

BRIEF-Nektar Therapeutics Announces Completion Of Target Enrollment In Rezolve-Ad Phase 2B Clinical Trial Of Rezpegaldesleukin In Patients With Moderate-To-Severe Atopic Dermatitis

Reuters
·
10 Jan

Nektar completes enrollment in REZOLVE-AD Phase 2b study of rezpegaldesleukin

TIPRANKS
·
10 Jan

Nektar Therapeutics Announces Completion of Target Enrollment in Rezolve-Ad Phase 2B Clinical Trial of Rezpegaldesleukin in Patients With Moderate-to-Severe Atopic Dermatitis

THOMSON REUTERS
·
10 Jan

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

PR Newswire
·
10 Jan

Nektar Therapeutics (NKTR) Gets a Buy from Piper Sandler

TIPRANKS
·
10 Jan

B. Riley Starts Nektar Therapeutics With Buy Rating, $4 Price Target

MT Newswires Live
·
08 Jan

U.S. RESEARCH ROUNDUP-GE Healthcare, Summit Materials, Tapestry

Reuters
·
08 Jan

Nektar Therapeutics : B. Riley Initiates Coverage With Buy Rating; Price Target $4

THOMSON REUTERS
·
08 Jan

Nektar initiated with a Buy at B. Riley

TIPRANKS
·
08 Jan

Nektar Therapeutics (NKTR) Gets a Buy from B.Riley Financial

TIPRANKS
·
08 Jan

Institutional investors have a lot riding on Nektar Therapeutics (NASDAQ:NKTR) with 68% ownership

Simply Wall St.
·
04 Jan

Promising Future for Nektar Therapeutics: Innovative Approach in Autoimmune Disease Treatment with Rezpegaldesleukin

TIPRANKS
·
12 Dec 2024

HC Wainwright Initiates Nektar Therapeutics at Buy With $6.50 Price Target

MT Newswires Live
·
10 Dec 2024

Nektar initiated with a Buy at H.C. Wainwright

TIPRANKS
·
10 Dec 2024

Nektar Therapeutics Announces Nktr-255 Following Cd19-Directed CAR-T Therapy Enhanced Complete Response Rates in Patients With Relapsed or Refractory Large B-Cell Lymphoma at the 66TH Annual Ash Meeting

THOMSON REUTERS
·
08 Dec 2024

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

PR Newswire
·
08 Dec 2024

Press Release: Ampersand Capital Partners Completes Acquisition of Nektar Therapeutics' PEG Reagent Manufacturing Business, Launching Newly Branded Gannet BioChem

Dow Jones
·
02 Dec 2024

Nektar presents preclinical data on NKTR-422 at ACR conference

TIPRANKS
·
19 Nov 2024

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

PR Newswire
·
19 Nov 2024

Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets

Simply Wall St.
·
10 Nov 2024